Although some evidence indicates that CXCR2 inhibition could prevent recruitment of CD11b+ Gr1+ myeloid cells in PTEN−/− prostate tumors (82), it remains unclear whether Ly6G+ neutrophil infiltration at the tumor site is impaired. This evidence concerns the gene CXCR2 and neoplasm.